Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03361748 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 149
- Enrollment target
NCT03361748 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 149 participants.
The verdict
NCT03361748, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 149 participants
- Enrollment target
Study Summary
This is an open label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture bb2121 chimeric antigen receptor (CAR) modified T cells. Prior to bb2121 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.
Interventions
- BIOLOGICAL bb2121
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2017-12-13 |
| Est. Completion | 2023-12-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03361748
The ClinicalTrials.gov registry entry for NCT03361748 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bb2121 is the first listed.
NCT03361748 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03361748 about?
NCT03361748 is a clinical study titled "Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma". This is an open label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture bb2121 chimeric antigen receptor (CAR) modified T cells. Prior to bb2121 i...
What is the current status of trial NCT03361748?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 149 participants. The study started on 2017-12-13. Estimated completion is 2023-12-20.
What interventions are being tested in trial NCT03361748?
The interventions under investigation include: bb2121 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03361748?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.